Bristol Myers vets tie up another all-stock deal, lining up clinical-stage oncology pipeline

John Carroll

Editor & Founder

A handful of Bristol Myers Squibb vets setting up a fledgling cancer drug developer have wrapped back-to-back stock deals to create a new oncology pipeline …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers vets tie up another all-stock deal, lining up clinical-stage oncology pipeline

John Carroll

Editor & Founder

Sign up to read this article for free.

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Bris­tol My­ers vets tie up an­oth­er all-stock deal, lin­ing up clin­i­cal-stage on­col­o­gy pipeline

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Bristol Myers vets tie up another all-stock deal, lining up clinical-stage oncology pipeline

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify